ArticleThe Journal of experimental medicine1997
Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.
Article in The Journal of experimental medicine, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 100 citations in OpenAlex.
- A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes.American journal of hematology · 2013Trial
- Glycated CD59: a novel biomarker for gestational diabetes.Endocrine reviews · 2026Review
- Genetic variants in the CD59 gene: An exploratory study of large genome databases.Transfusion · 2025Article
- SARS-CoV-2 hijacks host CD55, CD59 and factor H to impair antibody-dependent complement-mediated lysis.Emerging microbes & infections · 2024Article
- Structural basis for membrane attack complex inhibition by CD59.Nature communications · 2023Article
- Bispecific mAbInternational journal of molecular sciences · 2022Article
- How Structures of Complement Complexes Guide Therapeutic Design.Sub-cellular biochemistry · 2021Review
- A cryptic non-GPI-anchored cytosolic isoform of CD59 controls insulin exocytosis in pancreatic β-cells by interaction with SNARE proteins.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Overexpression of CD59 inhibits apoptosis of T-acute lymphoblastic leukemia via AKT/Notch1 signaling pathway.Cancer cell international · 2019Article
- Molecular pathogenesis of human CD59 deficiency.Neurology. Genetics · 2018Article
- Wireless control of cellular function by activation of a novel protein responsive to electromagnetic fields.Scientific reports · 2018Article
- Absence of CD59 in Guinea Pigs: Analysis of theJournal of immunology (Baltimore, Md. : 1950) · 2018Article
- A distinctive histidine residue is essential for in vivo glycation-inactivation of human CD59 transgenically expressed in mice erythrocytes: Implications for human diabetes complications.American journal of hematology · 2017Article
- Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.Journal of diabetes and its complications · 2017Article
- CD59 mediates cartilage patterning during spontaneous tail regeneration.Scientific reports · 2015Article
- Role of complement and complement regulatory proteins in the complications of diabetes.Endocrine reviews · 2015Review
- Human IgG1 Responses to Surface Localised Schistosoma mansoni Ly6 Family Members Drop following Praziquantel Treatment.PLoS neglected tropical diseases · 2015Article
- Structural basis for recognition of the pore-forming toxin intermedilysin by human complement receptor CD59.Cell reports · 2013Article
- On the three-finger protein domain fold and CD59-like proteins in Schistosoma mansoni.PLoS neglected tropical diseases · 2013Article
- Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.Muscle & nerve · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Ly-6 superfamily of cell surface molecules includes CD59, a potent regulator of the complement system that protects host cells from the cytolytic action of the membrane attack complex (MAC). Although its mechanism of action is not well understood, CD59 is thought to prevent assembly of the MAC by binding to the C8 and/or C9 proteins of the nascent complex. Here a systematic, structure-based mutational approach has been used to determine the region(s) of CD59 required for its protective activity. Analysis of 16 CD59 mutants with single, highly nonconservative substitutions suggests that CD59 has a single active site that includes Trp-40, Arg-53, and Glu-56 of the glycosylated, membrane-distal face of the disk-like extra-cellular domain and, possibly, Asp-24 positioned at the edge of the domain. The putative active site includes residues conserved across species, consistent with the lack of strict homologous restriction previously observed in studies of CD59 function. Competition and mutational analyses of the epitopes of eight CD59-blocking and non-blocking monoclonal antibodies confirmed the location of the active site. Additional experiments showed that the expression and function of CD59 are both glycosylation independent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.